We use both our own and third-party cookies for statistical purposes and to improve our services. If you continue to browse, we consider that you accept the use of these.

Predictive Diagnostics:

Matching cancer patients to treatment

Next-generation tools using the power of RNA

to predict patient response to immunotherapy

THE NEXT GENERATION OF PREDICTIVE DIAGNOSTICS

Cofactor has developed the first diagnostic that accurately predicts patient response to immunotherapy

The national PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial is evaluating use of Cofactor’s OncoPrism assay to effectively predict patients’ responses to immunotherapy. To date, more than 24 healthcare systems have partnered with Cofactor in the trial that will ultimately study 11 solid tumor cancers.

Better tools are needed to provide clinicians and patients with a more accurate understanding of tumor response ahead of treatment decisions,” explained Douglas Adkins, M.D., who led the study. “The use of multidimensional biomarkers rather than single analyte biomarkers represents a promising new approach.

INVESTORS

Help us write the next chapter in human health and precision medicine.

OUR TECHNOLOGY

Achieving true precision medicine requires a shift to multidimensional models.

LATEST NEWS

Get the latest news on how we’re changing the biotech industry.

CLIENTS & PARTNERS

WORKING WITH & SUPPORTED BY

INDICATIONS WE’RE PURSUING IN IMMUNE-ONCOLOGY

Are you a medical oncologist, pathologist, or other clinical researcher with an active interest in one of the indications shown below? Contact us to learn about our sponsored research programs.

Contact us to participate in one of our sponsored retrospective or prospective studies, with full support provided by Cofactor Genomics.

OUR DIAGNOSTIC PIPELINE

Feasibility Market & clinical need established
Immune Signal Biological signal detected
Sites Contracted Disease-expert partners
Biomarker Predictive biomarker established
Clinical Study Validation in progress
HNSCC
NSCLC
CRC
Urothelial
Melanoma

Contact us to join one of our clinical studies.

Contact Us


    *Required

    Start typing and press Enter to search